SCHEMBL4098201

SCHEMBL4098201

CCOC(=O)N1CCN(c2nc(-c3ccccc3Cl)nc3ccc(C(=O)N(CC)CC)cc23)CC1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 7/20 0.51
MEN1 O00255 6/20 0.51
TSPO P30536 2/20 0.46
KDM4E B2RXH2 2/20 0.46
ABCB1 P08183 1/20 0.45
ATM Q13315 1/20 0.44
ALDH1A1 P00352 3/20 0.43
HPGD P15428 3/20 0.43
LMNA P02545 2/20 0.43
HSD17B10 Q99714 2/20 0.43
CYP1A2 P05177 1/20 0.43
CYP3A4 P08684 1/20 0.43
CYP2D6 P10635 1/20 0.43
MAPT P10636 1/20 0.43
CYP2C19 P33261 1/20 0.43
TDP1 Q9NUW8 1/20 0.43
GBA1 P04062 1/20 0.42
ACACB O00763 1/20 0.42
ACACA Q13085 1/20 0.42
P2RY12 Q9H244 2/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4099459 0.93 KMT2A (0.51) KMT2AMEN1TSPOKDM4EABCB1
SCHEMBL4099970 0.90 MEN1 (0.52) KMT2AMEN1TSPOABCB1ALDH1A1
SCHEMBL4097518 0.88 MEN1 (0.53) KMT2AMEN1TSPOABCB1ALDH1A1
SCHEMBL4091440 0.87 KMT2A (0.55) KMT2AMEN1KDM4EABCB1ATM
SCHEMBL4093148 0.86 KMT2A (0.54) KMT2AMEN1KDM4EABCB1ATM
SCHEMBL4090994 0.86 CYP1A2 (0.50) KMT2AMEN1TSPOABCB1ALDH1A1
SCHEMBL4095953 0.85 MEN1 (0.67) KMT2AMEN1TSPOKDM4EABCB1
SCHEMBL4085061 0.85 MEN1 (0.53) KMT2AMEN1KDM4EABCB1ATM
SCHEMBL4095415 0.85 KMT2A (0.57) KMT2AMEN1KDM4EABCB1ATM
SCHEMBL13984095 0.85 KMT2A (0.49) KMT2AMEN1TSPOKDM4EABCB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090209536-A1 AMINOQUINAZOLINE CANNABINOID RECEPTOR MODULATORS FOR TREATMENT OF DISEASE KALYPSYS, INC. (US) 2009-08-20 US disclosed
US-20090209536-A1 AMINOQUINAZOLINE CANNABINOID RECEPTOR MODULATORS FOR TREATMENT OF DISEASE KALYPSYS, INC. (US) 2009-08-20 US disclosed
US-20090209536-A1 AMINOQUINAZOLINE CANNABINOID RECEPTOR MODULATORS FOR TREATMENT OF DISEASE KALYPSYS, INC. (US) 2009-08-20 US disclosed
WO-2008157500-A1 AMINOQUINAZOLINE CANNABINOID RECEPTOR MODULATORS FOR TREATMENT OF DISEASE KALYPSYS, INC. (US) 2008-12-24 WO disclosed
WO-2008157500-A1 AMINOQUINAZOLINE CANNABINOID RECEPTOR MODULATORS FOR TREATMENT OF DISEASE KALYPSYS, INC. (US) 2008-12-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090209536-A1 AMINOQUINAZOLINE CANNABINOID RECEPTOR MODULATORS FOR TREATMENT OF DISEASE CNR2, CNR1, GPR18 KMT2A 1424/4885MEN1 718/4885TSPO 202/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.